Glucagon-Like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Hyperglycemia and hypoglycemia currently are considered risk factors for cardiovascular disease in type 1diabetes. Both acute hyperglycemia and hypoglycemia induce endothelial dysfunction and inflammation, raising the oxidative stress. Glucagon-like peptide 1 (GLP-1) has antioxidant properties, and evidence suggests that it protects endothelial function. RESEARCH DESIGN AND METHODS: The effect of both acute hyperglycemia and acute hypoglycemia in type 1 diabetes, with or without the simultaneous infusion of GLP-1, on oxidative stress (plasma nitrotyrosine and plasma 8-iso prostaglandin F2alpha), inflammation (soluble intercellular adhesion molecule-1 and interleukin-6), and endothelial dysfunction has been evaluated. RESULTS: Both hyperglycemia and hypoglycemia acutely induced oxidative stress, inflammation, and endothelial dysfunction. GLP-1 significantly counterbalanced these effects. CONCLUSIONS: These results suggest a protective effect of GLP-1 during both hypoglycemia and hyperglycemia in type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the context of T2DM, GLP-1RAs have produced a range of beneficial pancreatic impacts, leading to significant enhancements in glycated hemoglobin (HbA1c), fasting and postprandial plasma glucose levels, and pancreatic beta-cell performance indicators.72–74”
From Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications (2024) · cites this paper as [72]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In people with T1D, GLP-1 infusion counteracted hypo- and hyperglycemia-induced increases in the inflammation markers IL-6 and soluble intercellular adhesion molecule-1 (sICAM-1) (45).”
From GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity (2025) · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
The Value of Cardiovascular Autonomic Function Tests: 10 Years Experience in Diabetes
Ewing, D. J., Martyn, C. N., Young, R. J., & Clarke, B. F. (1985) · Diabetes Care · doi:10.2337/diacare.8.5.491 · Cited by 1,434
Gold, A. E., Macleod, K. M., & Frier, B. M. (1994) · Diabetes Care · doi:10.2337/diacare.17.7.697 · Cited by 810
Nyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680
Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress
Mercuri, F., Tonutti, L., Taboga, C., Ceriello, A., Assaloni, R., Motz, E., & Quagliaro, L. (2001) · Diabetologia · doi:10.1007/s001250100529 · Cited by 419
Self-citationVascular disease and diabetes: Is hypoglycaemia an aggravating factor?
Wright, R. J., & Frier, B. M. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.865 · Cited by 336 · cited 2×
“Recent evidence suggests that hypoglycemia also may play an important role in favoring diabetic vascular complications (1).”
BackgroundAmiel, S. A., Tamborlane, W. V., Simonson, D. C., & Sherwin, R. S. (1987) · New England Journal of Medicine · doi:10.1056/nejm198705283162205 · Cited by 309
Oeseburg, H., de Boer, R. A., Buikema, H., van der Harst, P., van Gilst, W. H., & Silljé, H. H. W. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.206425 · Cited by 267
Cited by
Items 101–200 of 203
Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists
Tommerdahl, K. L., Nadeau, K. J., & Bjornstad, P. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.06.001 · Cited by 29
Sun, S., Zhang, H., Shan, K., Sun, T., Lin, M., Jia, L., & Chen, Y. Q. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201800987 · Cited by 23
Diabetes Mellitus in Acute Coronary Syndrome
Stampouloglou, P. K., Anastasiou, A., Bletsa, E., Lygkoni, S., Chouzouri, F., Xenou, M., Κατσαρού, Ο., Theofilis, P., Zisimos, K., Tousoulis, D., et al. (2023) · Life · doi:10.3390/life13112226 · Cited by 40
Microfluidic-based systems for the management of diabetes
Zhang, S., & Staples, A. (2024) · Drug Delivery and Translational Research · doi:10.1007/s13346-024-01569-y · Cited by 23
Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection
Bielka, W., Przezak, A., & Pawlik, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147605 · Cited by 23
Ceriello, A., Novials, A., Ortega, E., Canivell, S., Pujadas, G., Sala, L. L., Bucciarelli, L. G., Rondinelli, M., & Genovese, S. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-97 · Cited by 24
Self-citationAnti-inflammatory effects of GLP-1 in patients with COVID-19
Sazgarnejad, S., Yazdanpanah, N., & Rezaei, N. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1964955 · Cited by 21
Fan, X., Jiang, Y., Yu, Z., Yuan, J., Sun, X., Xiang, S., Lo, E. H., & Wang, X. (2014) · Advances in pharmacology · doi:10.1016/bs.apha.2014.06.007 · Cited by 22
Suhrs, H. E., Raft, K. F., Bove, K. B., Madsbad, S., Holst, J. J., Zander, M., & Prescott, E. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.12.005 · Cited by 21
Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. Reply.
Frías, J. P., Landó, L. F., & Brown, K. E. (2022) · PubMed · doi:10.1056/nejmc2114590 · Cited by 16
Омаровна, К. И., Zhernakova, Y. V., & Blinova, N. V. (2023) · Systemic Hypertension · doi:10.38109/2075-082x-2022-4-37-44 · Cited by 24
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
Cooper, M. E., & van Raalte, D. H. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194749 · Cited by 24
“In people with T1D, GLP-1 infusion counteracted hypo-and hyperglycemia-induced increases in the inflammation markers IL-6 and soluble intercellular adhesion molecule-1 (sICAM-1) (45).”
van der Heyden, J. C., Birnie, E., Mul, D., Bovenberg, S. A., Veeze, H. J., & Aanstoot, H. (2016) · BMC Endocrine Disorders · doi:10.1186/s12902-016-0129-3 · Cited by 18
Homolak, J., Perhoč, A. B., Knezović, A., Barilar, J. O., & Šalković‐Petrišić, M. (2021) · Antioxidants · doi:10.3390/antiox10071118 · Cited by 19
McCarthy, O. M., Moser, O., Eckstein, M. L., Bain, S. C., Pitt, J. P., & Bracken, R. M. (2019) · Nutrients · doi:10.3390/nu11071571 · Cited by 19
Jiaqiong, L., Li, X., Lin, Y., Huang, Z., & Wu, W. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11706 · Cited by 17
d’Aiello, A., Bonanni, A., Vinci, R., Pedicino, D., Severino, A., Vita, A. D., Filomia, S., Brecciaroli, M., & Liuzzo, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108643 · Cited by 19
The Role of Obesity as a Cardiac Disease Risk Factor in Patients with Type 2 Diabetes
Koirala, S., Sunnaa, M., Bernier, T. D., & Oktay, A. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02129-z · Cited by 17
Aini, K., Fukuda, D., Tanaka, K., Higashikuni, Y., Hirata, Y., Yagi, S., Kusunose, K., Yamada, H., Soeki, T., & Sata, M. (2019) · International Heart Journal · doi:10.1536/ihj.19-117 · Cited by 22
Impact of Glycemic Variability on Cardiovascular Risk in Diabetes
Klimontov, V. V. (2018) · Kardiologiia · doi:10.18087/cardio.2018.10.10152 · Cited by 17
Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists
Reed, J., Kanamarlapudi, V., & Bain, S. (2018) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000147 · Cited by 16
Król, M., Kupnicka, P., Żychowska, J., Kapczuk, P., Szućko-Kociuba, I., Prajwos, E., & Chlubek, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146777 · Cited by 19
Yang, Z., Tian, R., Zhang, X., Cai, J., She, Z., & Li, H. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1120085 · Cited by 26
Incretin and glucagon receptor polypharmacology in chronic kidney disease
McFarlin, B. E., Duffin, K. L., & Konkar, A. A. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2023 · Cited by 17
Dong, X., Guan, F., Xu, S., Zhu, L., Zhang, P., Cheng, A., & Liu, T. (2018) · Journal of Research in Medical Sciences · doi:10.4103/1735-1995.223951 · Cited by 15
Zheng, D., & Zhao, X. (2020) · World Neurosurgery · doi:10.1016/j.wneu.2020.01.042 · Cited by 15
GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease
Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01036-y · Cited by 22
Theofilis, P., Vordoni, A., & Kalaitzidis, R. (2022) · Life · doi:10.3390/life12101663 · Cited by 15
IGUDESMAN, D. A., Crandell, J., Corbin, K. D., Muntis, F. R., Zaharieva, D. P., Casu, A., Thomas, J. M., Bulik, C. M., Carroll, I. M., Pence, B. W., et al. (2022) · Current Developments in Nutrition · doi:10.1093/cdn/nzac107 · Cited by 17
Remm, F., Kränkel, N., Lener, D., Drucker, D. J., Sopper, S., & Brenner, C. (2018) · Stem Cells International · doi:10.1155/2018/5284963 · Cited by 14
Jahn, L. A., Logan, B. R., Love, K. M., Horton, W. B., Eichner, N. Z. M., Hartline, L. M., WELTMAN, A. L., & Barrett, E. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00267.2021 · Cited by 14
Ebbesen, M., Kissow, H., Hartmann, B., Grell, K., Gørløv, J. S., Kielsen, K., Holst, J. J., & Müller, K. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.01.036 · Cited by 16
Alharby, H., Abdelati, T., Rizk, M. M., Youssef, E. A., Gaber, N., Moghazy, K., & Yafei, S. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.01.031 · Cited by 15
Koh, G. Y., Rowling, M. J., Schalinske, K. L., Grapentine, K., & Loo, Y. T. (2016) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6b03808 · Cited by 15
Yao, M.-Y., Li, L.-Q., Ma, J.-X., Xue, P., & Li, Y.-K. (2020) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20198652 · Cited by 13
Johansen, N. J., Dejgaard, T. F., Lund, A., Schlüntz, C., Larsen, E. L., Poulsen, H. E., Goetze, J. P., Møller, H. J., Vilsbøll, T., Andersen, H. U., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14078 · Cited by 14
Ceriello, A., Sala, L. L., Nigris, V. D., Pujadas, G., Rondinelli, M., & Genovese, S. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s83322 · Cited by 13
Self-citationSørum, M. E., Kissow, H., Hartmann, B., Kielsen, K., Sørensen, K., Stinson, S. E., Frithioff‐Bøjsøe, C., Fonvig, C. E., Holm, J., Hansen, T. F., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.793588 · Cited by 14
Ceriello, A., Sala, L. L., Nigris, V. D., Pujadas, G., Testa, R., Uccellatore, A., & Genovese, S. (2015) · Endocrine · doi:10.1007/s12020-015-0565-2 · Cited by 11
Self-citationStabilizing Cellular Barriers: Raising the Shields Against COVID-19
Hanchard, J., Capó-Vélez, C. M., Deusch, K., Lidington, D., & Bolz, S.-S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.583006 · Cited by 10
Omachi, T., Ohara, M., Fujikawa, T., Kohata, Y., Sugita, H., Irie, S., Terasaki, M., Mori, Y., Fukui, T., & Yamagishi, S. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01493-3 · Cited by 11
Central Functions of Glucagon-like Peptide-1: Roles in Energy Regulation and Neuroprotection
McGrath, R. T. (2015) · Journal of Steroids & Hormonal Science · doi:10.4172/2157-7536.1000.152 · Cited by 8
Zhang, J., Ma, X., Liu, F., Zhang, D., Ling, J., Zhu, Z., Chen, Y., Yang, P., Yang, Y., Liu, X., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1203389 · Cited by 12
Colin, I. M., Colin, H., Dufour, I., Gielen, C.-E., Many, M., Saey, J.-P., Knoops, B., & Gérard, A.-C. (2016) · Physiological Reports · doi:10.14814/phy2.12886 · Cited by 8
RECAP study group, Tsukamoto, S., Kobayashi, K., Toyoda, M., Tone, A., Kawanami, D., Suzuki, D., Tsuriya, D., Machimura, H., Shimura, H., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15652 · Cited by 11
Blood–brain barrier disruption and edema formation due to prolonged starvation in wild-type mice
Hossain, M. I., Haque, M., Akter, M., Sharmin, S., & Ahmed, A. (2024) · Brain Circulation · doi:10.4103/bc.bc_88_23 · Cited by 9
Ceriello, A., Nigris, V. D., Pujadas, G., Sala, L. L., Bonfigli, A. R., Testa, R., Uccellatore, A., & Genovese, S. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.01.019 · Cited by 9
Self-citationLe, T. D., Nguyen, N. P. T., Nguyen, S. T., Nguyen, H. T. T., Tran, T. T. H., Nguyen, T. H. L., Nguyen, D. C., Nguyen, G. T., Nguyễn, X. T., Nguyen, B. D., et al. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s264876 · Cited by 11
Reytor-González, C., Cevallos-Fernández, E., Jácome, B., & Simancas-Racines, D. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1655889 · Cited by 9
Pathophysiology, prevention, and management of coronary microvascular obstruction
Cenko, E., Badimón, L., Vadalà, G., Merkus, D., Antoniades, C. A., Collet, C. A., Maria, G. L. D., Đorđević-Dikić, A., Drenjancevic, I., Escaned, J., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag334 · Cited by 9
Pan, L., Xu, M. J., Wang, Q., Zou, X., Han, Y., & Zhou, Z. (2021) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.11541 · Cited by 8
Effects of incretin therapy and bariatric surgery on inflammation in obese patients
Tardio, V., Kellett, S., Bidal-St-Aubin, M., & Tsoukas, M. A. (2018) · Obesity Medicine · doi:10.1016/j.obmed.2018.12.001 · Cited by 8
The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease
Guo, Z. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00609-1 · Cited by 8
McCarthy, O. M., Pitt, J. P., Churm, R., Dunseath, G. J., Jones, C., Bally, L., Nakas, C. T., Deere, R., Eckstein, M. L., Bain, S. C., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001577 · Cited by 8
Tiselko, A. V., Владимировна, М. Е., Yarmolinskaya, M. I., Milyutina, Y. P., Zalozniaia, I. V., & Валентинович, К. А. (2024) · Endocrine · doi:10.1007/s12020-024-03805-4 · Cited by 7
Hagve, M., Gjessing, P. F., Hole, M. J., Jansen, K. M., Fuskevåg, O., Mollnes, T. E., Larsen, T. S., & Irtun, Ø. (2019) · Endocrinology · doi:10.1210/en.2019-00374 · Cited by 7
Pollé, O. G., Ruys, S. P. D., Lemmer, J., Hubinon, C., Martin, M., Herinckx, G., Gatto, L., Vertommen, D., & Lysy, P. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-71717-4 · Cited by 7
Yang, X., & Liang, Z. (2018) · Herz · doi:10.1007/s00059-018-4748-5 · Cited by 6
Xu, Z., Ding, J., Zhang, L., Feng, X., Zhou, J., Shen, X., Lü, H., Qian, L., & Li, X. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.11937 · Cited by 5
IGUDESMAN, D. A., Crandell, J., Corbin, K. D., Zaharieva, D. P., Addala, A., Thomas, J. M., Bulik, C. M., Pence, B. W., Pratley, R. E., Kosorok, M. R., et al. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.11.017 · Cited by 9
Acute severe hypoglycemia alters mouse brain microvascular proteome
Sakamuri, S. S. V. P., Sure, V. N. L. R., Oruganti, L., Wisen, W. P., Chandra, P. K., Liu, N., Fonseca, V. A., Wang, X., Klein, J., & Katakam, P. V. G. (2023) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x231212961 · Cited by 7
Ye, S., He, D., Chen, T., Lan, K., Zhong, Y., Lai, Y., Wu, Y. F., & Mo, A. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.172329 · Cited by 6
Ferhatbegović, L., Bećirović, M., Bečirović, E., Sarajlić, S., Ribić, A., Šarić, A., Bećirović, A., & Pojskić, B. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2026.1765597 · Cited by 5
Targeting cardiometabolic risk in type 1 diabetes through incretin physiology
Frampton, R., HOCKING, S. L., SNAITH, J. R., & Greenfield, J. R. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.06.004 · Cited by 4
Albuminuria and cardiorenal risk
Georgianos, P. I., Dounousi, E. C., & Liakopoulos, V. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001055 · Cited by 5
Badavi, M., Bazaz, A., Dianat, M., & Sarkaki, A. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12513 · Cited by 5
Boccatonda, A., D’Ardes, D., Brighenti, A., Cipollone, A., Simeone, P., Guagnano, M. T., Serra, C., Santilli, F., & Cipollone, F. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113271 · Cited by 3
Glucagon-like peptide-1 and impaired counterregulatory responses to hypoglycemia in type 1 diabetes
Rocha, G. R., & de Melo, F. F. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.99928 · Cited by 4
Lovre, D., Htun, W., Carrion, C., & Fonseca, V. A. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0788-5 · Cited by 3
Kazkayası, İ., Telli, G., Balcı, A., & Serdar, U. (2022) · Journal of Research in Pharmacy · doi:10.29228/jrp.150 · Cited by 2
Severity of Symptoms and Mortality in Diabetic Patients with COVID- 19 Infection. Review
Albasry, Z., Rashid, A. A., & Abbas, S. H. (2023) · Al Mustansiriyah Journal of Pharmaceutical Sciences · doi:10.32947/ajps.v23i1.991 · Cited by 3
Yahaya, T., Sifau, M. O., Oladele, E. O., Bashar, D. M., Abubakar, A. L., Salisu, N., Usman, B. M., & Koko, J. D. (2022) · Folia Medica Indonesiana · doi:10.20473/fmi.v58i2.33988 · Cited by 3
Therapeutic Considerations in Preventing Chronic Kidney Disease
Nicholas, S. B., Nobakht, N., & Alicic, R. Z. (2025) · Annual Review of Medicine · doi:10.1146/annurev-med-043024-013325 · Cited by 2
Platelet mitochondria dysfunction in diabetes mellitus: mechanisms and therapeutic implications
Yadava, S., Dontiboina, H. R., Dugluri, S., Yadagiri, G., Choudhury, P., & Kakarla, R. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1774791 · Cited by 2
Chang, Y., Zhang, C., Li, Z., Wang, S., Wu, J., Xie, J., & Cheng, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1739048 · Cited by 3
Yu, Y., Ding, L., Huang, H., Cheng, S., Deng, Y., Cai, C., Gu, M., Chen, X., Niu, H., & Hua, W. (2024) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223231223285 · Cited by 2
Gupta, N., Uwawah, T. D., Singh, K., Madan, H., Kumar, S., Midha, B., Soni, K., Singh, A., Bhogal, A., & Jain, A. (2024) · Cureus · doi:10.7759/cureus.64668 · Cited by 4
Are the lipid-lowering effects of incretin-based therapies relevant for cardiovascular benefit?
Alnima, T., Smits, M. M., & Hanssen, N. M. J. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000949 · Cited by 3
Papachristoforou, E., Kountouri, A., Maratou, E., Kouretas, D., Skaperda, Z., Tsoumani, M. E., Efentakis, P., Ikonomidis, I., Lambadiari, V., & Makrilakis, K. (2022) · Healthcare · doi:10.3390/healthcare10081509 · Cited by 5
Grigoriou, K., Karakasis, P., Lamprou, V., Michas, G., Pamporis, K., Trikas, A. G., Pantos, C. I., & Mourouzis, I. S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1696749 · Cited by 1
Xanthopoulou, M., Evangelidis, P., Poulis, D., Gavriilaki, E., Kotsiou, N., Antza, C., Kotsis, V., Doxani, C., Mprotsis, T., Zintzaras, E., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19030462 · Cited by 2
CKD and Cerebral Microbleeds: Pathophysiologic Insights and Implications for Nephrology
Lee, S.-H., Ryu, J., Minasyan, M., Lau, W. L., & Fisher, M. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001067 · Cited by 1
Micalo, L., Archie, M. M., Rowe, V. L., Adewale, A. P., Pham, N. V., Li, A., & Jimenez, J. C. (2026) · Journal of Vascular Surgery Venous and Lymphatic Disorders · doi:10.1016/j.jvsv.2026.102557 · Cited by 2
Inflammation as a therapeutic target to improve kidney and cardiovascular outcomes
Tuttle, K. R., Kanbay, M., Alicic, R. Z., Carrero, J. J., Çöpür, S., Navar, A. M., Neuen, B. L., Perkovic, V., Rossing, P. R., Marx, N., et al. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-026-01117-6 · Cited by 4
SGLT2 Inhibitors and GLP1 Antagonists on Diabetes and Cardiovascular Disease
FITCHETT, D. H. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_33 · Cited by 1
Yu, J., Song, B., Zhu, Y., Wang, J., & Zhang, Y. (2024) · Journal of orthopaedic surgery · doi:10.1177/10225536241241890 · Cited by 1
A mini review on glucagon-like peptide-1 receptor agonists and its role in blood pressure regulationPreprint
Alharbi, N. H. J. (2024) · Preprints.org · doi:10.20944/preprints202402.0005.v1
Ceriello, A., & Genovese, S. (2016) · Diabetes · doi:10.2337/db15-1344
Self-citationResistant starch: implications in kidney health and vitamin D homeostasis in diabetes mellitus
Koh, G. Y. (2015) · Iowa State University Digital Repository (Iowa State University) · doi:10.31274/etd-180810-4402 · Cited by 1
Central Functions of Glucagon-like Peptide-1: Roles in Energy Regulation and
McGrath, N., Glastras, S. J., HOCKING, S. L., Tjoeng, I., Krause, M., Fulcher, G. R., & McGrath, R. T. (2015)
Glucagon Like Peptide-1: More than Glucose Control and Weight ReductionPreprint
Chen, Y., Shao, S., Zhang, X., Xu, Q., & Pan, R. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4161722
Brunori, G. (2022) · The Journal of AMD · doi:10.36171/lamd22.25.3.3
Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes
Hong, S. (2023) · BIO Web of Conferences · doi:10.1051/bioconf/20236101006
Nielsen, T. A. (2023) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau588597746
Amanat, M., Tandon, S., & Singh, R. (2025) · Current Diabetes Reviews · doi:10.2174/0115733998341202241202103725
Moin, A. S. M., Darwish, R., Sathyapalan, T., Atkin, S. L., & Butler, A. E. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.113076
Type 1 Diabetes: Pathophysiology and Treatment Considerations for Cardiovascular Risk and Disease
Tommerdahl, K. L., & Bjornstad, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00005-7
AbdelMagid, A. M., Kamel, A. M., & Farid, S. F. (2026) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.70142
Venkatesan, A., Martin, A., Katragadda, N., Tsui, S., Otten, M., Lee, R., & Sharma, G. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001330
Metadata
- Authors
- Ceriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Esposito, K., Giugliano, D., & Genovese, S.
- Affiliations
- Centro de Investigación Biomédica en Red Diabetes y Enfermedades Metabólicas Asociadas (ES)
- Diabetes and Endocrinology, Insititut d'Investigacions Biomèdiques August Pi i Sunyer and Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Hospital Clínic Barcelona, Barcelona, Spain
- University of Campania "Luigi Vanvitelli" (IT)
- MultiMedica (IT)
- Corresponding author
- Ceriello, Antonio
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-07-11
- Volume
- 36
- Issue
- 8
- Pages
- 2346-2350
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3714509
- OpenAlex
- W2148254941
- Cited by
- 204
- References
- 28
- Citations by year
- 2026: 16 · 2025: 11 · 2024: 16 · 2023: 19 · 2022: 16 · 2021: 23 · 2020: 12 · 2019: 17 · 2018: 10 · 2017: 9 · 2016: 22 · 2015: 19 · 2014: 10 · 2013: 4
- FWCI
- 14.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Keywords
- glucagon-like peptide-1, type 1 diabetes, hyperglycemia, hypoglycemia, endothelial dysfunction, oxidative stress, inflammation, nitrotyrosine, 8-isoprostane, interleukin-6, soluble intercellular adhesion molecule-1, cardiovascular risk
- MeSH terms
- Adult, Blood Glucose, Diabetes Mellitus, Type 1, Endothelium, Vascular, Female, Humans, Hyperglycemia, Hypoglycemia, Inflammation, Male, Interleukin-6, Oxidative Stress, Intercellular Adhesion Molecule-1, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.